Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Buy
60
TIL Quote, Financials, Valuation and Earnings
Last price:
$36.35
Seasonality move
:
27.74%
Day range:
$34.76 - $41.50
52-week range:
$9.62 - $92.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.66x
Volume:
499.2K
Avg. volume:
367.4K
1-year change:
237.27%
Market cap:
$239.8M
Revenue:
--
EPS (TTM):
-$11.97
Analysts' Opinion
-
Consensus RatingInstil Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $118.67, Instil Bio has an estimated upside of 224.58% from its current price of $36.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $51.00 representing 100% downside risk from its current price of $36.56.
Fair Value
-
According to the consensus of 3 analysts, Instil Bio has 224.58% upside to fair value with a price target of $118.67 per share.
TIL vs. S&P 500
-
Over the past 5 trading days, Instil Bio has overperformed the S&P 500 by 5.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Instil Bio does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Instil Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Instil Bio reported revenues of --.
Earnings Growth
-
Instil Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Instil Bio reported earnings per share of -$4.32.
Enterprise value:
220.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.84x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$182.9M | -$72.9M | -$50.8M | -$19.7M | -$14.5M | |
| EBITDA | -$218.6M | -$114M | -$68M | -$21.6M | -$26.8M | |
| Diluted EPS | -$34.77 | -$18.97 | -$11.97 | -$3.74 | -$4.32 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $613.8M | $390.7M | $240.1M | $161M | $219.3M | |
| Total Assets | $696.1M | $564.9M | $427.2M | $306.3M | $237.4M | |
| Current Liabilities | $17.3M | $36.8M | $26.7M | $11.4M | $7.2M | |
| Total Liabilities | $31M | $56.4M | $116M | $100.5M | $92.5M | |
| Total Equity | $665.2M | $508.6M | $311.2M | $205.8M | $144.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$159.8M | -$61.8M | -$45.5M | -$14.4M | -$4.2M | |
| Cash From Investing | $51.2M | $35.8M | $54.3M | $9.2M | $9.6M | |
| Cash From Financing | $76M | $3.6M | $2M | -- | $232K | |
| Free Cash Flow | -$232.6M | -$74M | -$45.5M | -$14.4M | -$4.2M | |
TIL
Sector
Market Cap
$239.8M
$34.2M
Price % of 52-Week High
39.74%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
237.27%
-35.99%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$33.30
200-day SMA
Buy
Level
$25.91
Bollinger Bands (100)
Buy
Level
14.38 - 25.58
Chaikin Money Flow
Sell
Level
-61.7M
20-day SMA
Buy
Level
$25.63
Relative Strength Index (RSI14)
Buy
Level
69.14
ADX Line
Buy
Level
42.09
Williams %R
Neutral
Level
-25.5433
50-day SMA
Buy
Level
$19.12
MACD (12, 26)
Buy
Level
5.26
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Sell
Level
-26.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Stock Forecast FAQ
In the current month, TIL has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TIL average analyst price target in the past 3 months is $118.67.
-
Where Will Instil Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Instil Bio share price will rise to $118.67 per share over the next 12 months.
-
What Do Analysts Say About Instil Bio?
Analysts are divided on their view about Instil Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Instil Bio is a Sell and believe this share price will drop from its current level to $51.00.
-
What Is Instil Bio's Price Target?
The price target for Instil Bio over the next 1-year time period is forecast to be $118.67 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is TIL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Instil Bio is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TIL?
You can purchase shares of Instil Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Instil Bio shares.
-
What Is The Instil Bio Share Price Today?
Instil Bio was last trading at $36.35 per share. This represents the most recent stock quote for Instil Bio. Yesterday, Instil Bio closed at $36.56 per share.
-
How To Buy Instil Bio Stock Online?
In order to purchase Instil Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 29.48% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 20.55% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 17.78% over the past day.
